Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 3/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16618378 | 0.79 | NOS1 (0.39) | ELANENOS1FBP1F2PLAU | |
| SCHEMBL17276892 | 0.76 | NOS1 (0.39) | ELANENOS1FBP1TSHR | |
| SCHEMBL425530 | 0.76 | ELANE (0.47) | ELANEKMT2A | |
| SCHEMBL31253394 | 0.75 | NOS1 (0.46) | ELANENOS1FBP1F2PLAU | |
| SCHEMBL1680220 | 0.75 | — | — | |
| SCHEMBL23638637 | 0.74 | NOS1 (0.44) | ELANENOS1FBP1F2PLAU | |
| SCHEMBL6220651 | 0.74 | — | — | |
| SCHEMBL1021803 | 0.74 | NOS1 (0.52) | ELANENOS1FBP1F2PLAU | |
| SCHEMBL14385408 | 0.74 | NOS1 (0.52) | ELANENOS1FBP1F2PLAU | |
| SCHEMBL23407929 | 0.74 | NOS1 (0.44) | ELANENOS1FBP1F2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0673783-B1 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORP (US) | 2000-07-05 | — | — | EP | claimed |
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-10-23 | — | — | US | disclosed |
| CN-120035594-A | Heteroaromatic macrocyclic ether chemotherapeutic agents | 纽威伦特公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-118344342-A | Substituted polyaromatic ring derivatives, compositions and uses thereof | 康迈迪森(北京)医药科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-105611933-A | Antiproliferative compounds | GENENTECH INC | 2016-05-25 | — | — | CN | disclosed |
| US-8283358-B2 | N-sulfonamido polycyclic pyrazolyl compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ROS1, MCL1, ALK | ELANE 3336/4885NOS1 3744/4885FBP1 811/4885 |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | PSEN1, PSEN2, SULT1E1 | ELANE 3833/4885NOS1 80/4885FBP1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.